The US FDA has approved 3 NDAs and 2 BLAs in April 2021, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation […]readmore
Tags : ADC Therapeutics
Shots: The approval is based on data from the P-II LOTIS-2 trial involves assessing Zynlonta in adults with r/r DLBCL following two or more prior lines of systemic therapy Results: […]readmore
Shots: ADC Therapeutics’s to utilize Freenome’s multiomics platform to identify biomarkers correlating with clinical response to ADC’s ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma […]readmore
Shots: The companies enter into a collaboration to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine). ADC Therapeutics is currently assessing ADCT-402 in P-II study in patients […]readmore
Shots: Adagene to receive upfront, development & commercial milestones, research funding and royalties on sales with certain commercialization rights for Greater China. ADC Therapeutics to utilize Adagene’s SAFEbody technology generating […]readmore